Precision Biosensor, Inc. engages in the provision of solutions for Point-of-care Testing (POCT) through the development and commercialization of biomarker diagnostic products. Its products include Exdia TRF Plus, an immunodiagnosis POCT platform which enhances sensitivity based on TRF technology, and Exdia PT10 and Exdia PT10S, a clinical chemistry POCT platform which provides all-in-one diagnostic service based on multiplex technology. The company was founded on September 28, 2009 and is headquartered in Daejeon, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company